KDR and cancer: The combination of VEGFR TKIs with ICIs in RCC, HCC, NSCLC, mucosal melanoma, endometrial carcinoma, esophageal carcinoma, triple-negative breast cancer, microsatellite stability (MSS) gastric carcinoma (GC) and CRC, head and neck squamous cell carcinoma, urothelial carcinoma, osteosarcoma, and other malignant tumors has been associated with favorable outcomes (104).